Accuray Incorporated
Accuray Incorporated (ARAY) designs and sells precision radiation therapy systems used to treat cancer, including the CyberKnife and Radixact platforms. The company supplies hardware, software and ongoing services to hospitals and cancer centres worldwide. With a modest market capitalisation of about $181.48M, Accuray is a small-cap medical‑devices business where revenue can be driven by equipment sales, upgrade cycles and recurring service or software contracts. Investors should note the typical industry dynamics: long capital outlays by customers, regulatory oversight, and competition from larger vendors. That combination can create periodic volatility in sales and margins. Accuray’s prospects hinge on product adoption, technological differentiation and stable service revenues, but there are execution and market‑share risks. This summary is educational only and not investment advice; individual suitability depends on your goals, timeframe and risk tolerance. Past performance is not a reliable indicator of future results and values can fall as well as rise.
Stock Performance Snapshot
Analyst Rating
Analysts strongly recommend buying Accuray's stock with a target price of $3.88, indicating significant upside.
Financial Health
Accuray is generating modest revenue and cash flow, but faces challenges in profitability.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring ARAY
Healthcare's Compliance Catalyst
The Department of Justice's investigation into UnitedHealth's billing practices is increasing pressure on the entire healthcare industry to ensure compliance. This regulatory focus creates an investment opportunity in companies that provide specialized technology for transparent and accurate medical billing.
Published: July 26, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Adoption and upgrades
Equipment sales and upgrade cycles can drive revenue spikes, though buying decisions by hospitals are often lengthy and cyclical.
Technology edge
Differentiation via accuracy, software and workflow matters for market share, but competitors and regulatory hurdles can slow uptake.
Service revenues matter
Recurring service and software contracts can stabilise cash flow, yet overall performance will still vary and is not guaranteed.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
Abbott Laboratories
Abbott Laboratories is a global healthcare company that develops and markets a broad range of health care products, including medical devices, diagnostics, nutritionals, and branded generic pharmaceuticals.
Agilent Technologies Inc.
Agilent Technologies, Inc. specializes in life sciences, diagnostics and applied markets, providing application-focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. Its segments include Life Sciences and Diagnostics Markets, Agilent CrossLab and Applied Markets. Life Sciences and Diagnostics Markets segment comprises seven areas of activity. It offers active pharmaceutical ingredients for oligo-based therapeutics as well as solutions that include reagents, instruments, software and consumables. Agilent CrossLab segment offers a services and consumables portfolio that spans the entire lab, in addition to software and laboratory automation solutions, which are designed to enhance customer outcomes. Applied Markets segment offers application-focused solutions that include instruments and software that enable customers to identify, quantify and analyze the physical and biological properties of substances and products.
Align Technology Inc.
Align Technology is a medical device company that designs, manufactures and markets a range of dental and orthodontic products.
